WaisFix100™ is a groundbreaking solution for the treatment of proximal femoral fracture, a major market within trauma care. In 2005 the orthopaedic market generated sales of approximately $17 billion and trauma segments is approximately 35% of this market. There are at least 1.5million new fractures in the US each year. Current fixation failure rates for femoral fractures are high using current surgical methods; fractures have average failure rates of up to 45%. WaisFix100™ is the first commercially available device that reduces morbidity and mortality by increasing recovery rates and reducing blood loss and damage to tissue. The WaisFix100™ fixation device is designed to provide benefits such as minimally invasive accelerated fixation and early weight-bearing.
The chief scientist of the company is Dr Mark Waisman ,a senior orthopedic surgeon and head of the spine unit at Carmel Medical Centre, Haifa, Israel. He has been widely published in leading orthopedic journals including the Journal of Trauma.
OrthoMediTec has been approved for clinical trials in humans by the Israeli Helsinki Committee and it has conducted its first WaisFix100i™ clinical trial in Carmel Medical Centre, Haifa, Israel.
